GlassScriptPhysician profile
Christopher M Tolleson
NPI 1225159890
$28,226.93
in general payments reported to CMS, 2019-2025
47 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $1,018 · 2021: $1,391 · 2022: $653 · 2023: $2,059 · 2024: $2,156 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,358 · Consulting Fee: $1,600 · Travel and Lodging: $918 · Education: $30.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.66 |
| Consulting Fee | $1,600.00 |
| Travel and Lodging | $917.78 |
| Education | $30.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,724.61 | 2019-2025 | Duopa, Botox |
| Neurocrine Biosciences, INC. | $5,729.74 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $5,171.97 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Boston Scientific Corporation | $1,356.13 | 2019-2025 | General - Dbs, Vercise |
| Medtronic, INC. | $1,302.70 | 2022-2025 | Percept PC Brainsense, Sensight |
| Medtronic USA, INC. | $360.11 | 2019-2020 | |
| Allergan, INC. | $292.22 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $292.10 | 2021-2025 | Crexont, Rytary |
| Revance Therapeutics, INC. | $253.15 | 2024-2025 | Daxxify |
| Adamas Pharmaceuticals, INC. | $210.68 | 2019-2021 | |
| Kyowa Kirin, INC. | $188.78 | 2019-2024 | Nourianz |
| Ucb, INC. | $188.51 | 2019-2023 | Briviact |
| Acadia Pharmaceuticals INC | $176.55 | 2019-2024 | Nuplazid |
| Mdd US Operations, LLC | $170.06 | 2019-2025 | Apokyn, Gocovri |
| Novartis Pharmaceuticals Corporation | $166.59 | 2019-2020 |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tolleson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.